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Summary. The role of the family history äs a tool for the
diagnosis of inherited thrombophilia has not been estab-
lished. Several authors have indicated that a positive family
history is not a good predictor of inherited abnormalities
such äs antithrombin III deflciency, or deficiencies of protein
C or protein S. We have tried to approach the family history
in a quantitative way. To this end we used the cumulative
incidence data of thrombosis in the general population and
also in a population of protein C deflcient families to estimate
the expected number of symptomatic subjects in a family
under both the hypothesis of inherited thrombophilia and
the null-hypothesis. Although a number of assumptions
underlying our calculations need to be verified and probably
adjusted before any truly quantitative meaning can be
assigned to this approach, we feel that the family history is a
useful diagnostic test for inherited thrombophilia if it is used
in a critical way.
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Inherited venous thrombophilia has been an area of intense
clinical research since the description of the deficiency of
antithrombin III (Egeberg, 1965), protein C (Griffin et al,
1981; Bertina et al, 1982; Broekmans et al, 1983) and
protein S (Comp et al, 1984; Broekmans et al, 1985). The
family history is considered äs an important tool for the
distinction between sporadic and familial cases of venous
thrombo-embolic disease. This distinction is important for
two reasons. Firstly, the suspicion of an inherited tendency
to thrombosis justifles the request of fairly extensive
laboratory tests for individual patients. Secondly, the
search for 'new causes' of inherited thrombophilia requires
a panel of families with idiopathic familial thrombophilia.
New tests can then be applied in such families. Using this
approach we analysed the genes for thrombomodulin and
tissue factor pathway inhibitor in the Index cases of 30
families with unexplained familial venous thrombophilia
without flnding any abnormality (P. H. Reitsma et al,
unpublished observations). For this approach to be success-
ful, however, we need a criterion to decide whether the
thrombosis in a family is likely to be associated with an
inherited trait.
The purpose of this study was to quantitate the likelihood
that thrombosis in a particular family is associated with an
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inherited abnormality, even if that abnormality defles
laboratory Identification.
MATERIALS AND METHODS
Cumulative thrombosis incidence in the general population.
The catchment area of the Leiden regional anticoagulation
clinic comprises about 500000 inhabitants. Any patient
requiring treatment with oral anticoagulants within this
area is referred to the anticoagulation clinic for monitoring
of the intensity of the treatment. For each paüent the
indications for the treatment are registered in a Computer
database; also personal data, accompanying illnesses, all
prothrombin times, dosages, and complications.
To calculate the numerators for age-speciflc thrombosis
incidence rates we extracted all subjects from the Computer
flies who were treated for a first episode of deep vein
thrombosis or pulmonary embolism during 1986 and their
age at the time of diagnosis. Unfortunately, the use of
objective diagnosis for deep vein thrombosis was (and still is)
not used in all cases. The denominators were obtained using
the population data from the municipal registries of the same
catchment area. The number of new cases of deep vein
thrombosis of pulmonary embolism within each 5-year age
interval were divided by the total number of thrombosis-free
patient-years in the Leiden area within that age class, over
the l year period of follow-up. Subsequently, cumulative
incidences, i.e. the probabilities of having had a first
thrombotic episode before a given age, were calculated
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from equation l (Rothman, 1986):
C I = = 1_ e-E(txiR) (1)
where Cl = cumulative incidence, e = base of the natural
logarithm, i = width of the time intervals (5 years) and IR =
age-specific incidence rates. Finally, a graph was made by
plotting the cumulative incidences against age.
Cumulative thrombosis incidence in protein C deficiency. A
cumulative incidence of first episodes of deep vein thrombo-
sis or pulmonary embolism in protein C deficiency was
obtained from data on 75 subjects with a DNA-based
diagnosis of protein C deficiency from 20 different families
(Allaart et al, 1993). In order to avoid bias, all index cases
from these families were excluded.
Expected number of symptomatic subjects within a family.
Using the cumulative incidence plots we can predict the
probability to have had at least one episode of deep vein
thrombosis or pulmonary embolism for any person of a
particular age in a pedigree. This probability can be
calculated under the hypothesis that the family is not
affected by an inherited risk factor for thrombophilia by
using the cumulative incidence graph for the population and
the age of the subject. On the other hand, in order to
calculate the probability under the hypothesis that the
family is affected by protein C deficiency or a risk factor of
similar strength, we use both the cumulative incidence plot
for the population and the plot for the protein C deficient
subjects. In this case, the probability to have had at least one
thrombotic episode is given by the following equation:
(2)"sympt — Pnon-def x dnon-def + Pdef x
where Psympt = the probability to have suffered one or more
episodes of deep vein thrombosis or pulmonary embolism at
the relevant age, Pnon_aef = the probability not to have
inherited the deficiency based on the assumption that the
index case is deficient and the deficiency is transmitted in an
autosomal dominant fashion, CInon.def = the cumulative
incidence of deep vein thrombosis or pulmonary embolism at
the relevant age for subjects in the population at large,
Frier = the probability to have inherited the deficiency based
on the assumption that the index case is deficient and the
deficiency is transmitted in an autosomal dominant fashion
(Pdef = l ~Pnon-def)' CIdef = the cumulative incidence of
deep vein thrombosis or pulmonary embolism at the relevant
age for subjects with protein C deficiency. The expected total
number of symptomatic relatives is obtained by adding up
the individual probabilities for all the subjects in the pedigree
of the index case.
The probability that the index case has an inherited risk factor.
This calculation requires three sources of information,
which are combined using Bayes' theorem:
1. Information on the family 'anterior to' the index case,
i.e. the number of symptomatic relatives observed in relation
to the number of symptomatic relatives äs expected under
both hypotheses; for the sake of simplicity we have not taken
into account information about the descendents ('posterior
to') of the index case,
2. Information about the index case, i.e. the age at which
he suffered his first DVT,
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Fig 1. The cumulative incidence of thrombosis in patients with
definite protein C deficiency (n) and in the general population (·).
3. The prevalence of the hereditary traits.
Ad 1. To calculate the ratio of the likelihood favouring
inherited thrombophilia of the family (LRfamily) under the
hypothesis that the index case has an inherited risk factor
and the likelihood of the family under the hypothesis that the
index case does not have an inherited risk factor, it is
assumed that the number of symptomatic relatives under
both hypotheses follows a Poisson distribution. This means
that under both hypotheses the means and the variances are
equal. In practice this assumption is reasonable, although
the variance will be a little smaller than the corresponding
mean. The calculation is given in equation 3 (Sackett et al,
1985):
LRfanu,y = exp obs x
V A'chance
(3)
where obs = number of relatives observed to be sympto-
matic, Pmherited = the expected number of symptomatic
relatives under the hypothesis of inherited thrombophilia,
and /ichance = the expected number of symptomatic relatives
under the null-hypothesis.
Ad 2. From Fig l we can predict that the index case at age
48 has a 47% probability to have suffered a venous thrombo-
embolic event under the thrombophilia hypothesis and a 2%
probability under the null-hypothesis. This implies a
likelihood ratio (LRmdex) favouring thrombophilia of 47/2.
Although it would be better to use the age-specific incidence
at age 48 instead of the cumulative incidence up to age 48,
our approach allows for easy application of the two curves
and is a reasonable estimate.
Ad 3. We assume a prevalence (p0) of inherited
thrombophilia traits of slightly over 5% in the population
(Miletich et al, 1987; Tait et al, 1993; Koster et al, 1993).
The final probability Pflna| for the index case to have inherited
a thrombophilia gene is calculated by multiplying the
two likelihood ratios and by subsequently using Bayes'
theorem (Bayes, 1763) to combine the prevalence p0 with
the combined likelihood ratio (LRcombmed) äs shown in
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Table I. Age-specific incidence rates and cumulative incidences of thrombosis in the population of the Leiden
regional anticoagulation clinic.
Age (years)
0-4
5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-
Population* (No.)
26259
26900
28044
34874
38335
35497
30977
32496
27319
21581
18599
16478
14394
11841
9986
7504
7688
No. of cases
0
0
1
4
19
8
15
20
25
25
35
23
39
42
58
58
82
Incidence rate
(per 1000 per year)
0-00
0-00
0-04
0-11
0-50
0-23
0-48
0-62
0-92
1-16
1-88
1-40
2-71
3-55
5-81
7-73
10-67
Cumulative incidencef
0-000
0-000
0-000
0-001
0-003
0-004
0-007
0-010
0-014
0-020
0-029
0-036
0-049
0-066
0-092
0-127
0-172
* Thrombosis-free population was calculated by correcting the population number for the cumulative
incidence in the previous age category.
t See Methods.
equations 4 and 5:
LRfamily x LR index = LRcomb
r, LRcombined X Po
LRcombined x Po + l ~ Po
RESULTS
*· ' The population-based age-specific incidence rates for deep
vein thrombosis and pulmonary embolism in the catchment
{ ' area of the Leiden anticoagulation clinic, and also the
cumulative incidences for each of the age intervals, are
presented in Table I. Based on these data and the data from
Allaart et al (1993), a graph was made of cumulative
I I I 1 2 3 4 5
1/8 l/B 1/8 1/8
Fig 2. The pedigree of an imaginary index case (ΠΙ.4). Assuming that the index case has an autosomal dominant inherited thrombophilia trait we
calculated the probabilities for the relatives to have the same abnormality; the probability is indicated below each subject. Men are indicated by
Π. women by O t deceased subjects by an oblique line, and the index case by an arrow.
Table Π. Life-time thrombosis risk for the relatives of the index case,
calculated for the null hypothesis äs well äs the thrombophilia
hypothesis.
Risk to have had DVT or PE
Subject
1.1
1.2
1.3
1.4
Π.1
Π.2
Π.3
Π.4
Π. 5
Π. 6
m.i
m.2
ra.3
ffl.4
m. s
ffl.6
m. 7
m.8
m.9
ra.io
m. 11
ra.i2
Age*
83
62
80
86
72
77
78
82
80
25
54
52
50
48
44
48
46
42
54
52
49
47
Null hypothesis
0-172
0-049
0-172
0-172
0-092
0-127
0-127
0-172
0-172
0-004
0-029
0-029
0-029
Index case
0-014
0-020
0-020
0-014
0-029
0-029
0-020
0-020
Thrombophilia hypothesis
0-717
0-666
0-717
0-717
0-717
0-717
0-717
0-717
0-717
0-161
0-500
0-500
0-500
Index case
0-427
0-473
0-473
0-427
0-500
0-500
0-473
0-473
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Table III. Final probability of inherited thrombophilia for the index
case in the family shown in Fig 2, based on the data of Table H, the
assumption that the prevalence of inherited thrombophilia genes is
5% in the population, and the assumption that the occurrence of
thrombotic events follows a Poisson distribution.*
No. of
symptomatic
relatives
Unknown
0
1
2
3
4
5
LRfamily
1
0-06
0-17
0-50
1-4
4-1
11-8
LR
mdra
DVT at age 48
47/2
47/2
47/2
47/2
47/2
47/2
47/2
Final
probability
0-55
0-07
0-17
0-38
0-63
0-84
0-94
* See Methods for explanation.
From Fig l we also obtained the likelihood ratio favouring
thrombophilia for the index case. At the age of the index case
(48 years) this ratio amounted to 47/2. Subsequently, by
combining the two likelihood ratios and the prevalence,
the final probability of inherited thrombophilia in the index
case was calculated for varying numbers of symptomatic
relatives. The results of this calculation are shown in Table
III and clearly indicate the important contribution of the
family history.
* At death or current.
incidence versus age, both for the population-based data and
for the subjects with protein C deficiency (Fig 1).
In order to illustrate the use of these data for the prediction
of the number of symptomatic subjects within the family of
an index case, we present the pedigree of an imaginary
patient with deep vein thrombosis (ΙΠ.4) in Fig 2. Using the
age of the relatives and the population-based plot of Fig l, we
first calculated the risk to have had deep vein thrombosis or
pulmonary embolism for each relative under the hypothesis
that the family is not affected by an inherited risk factor for
venous thrombosis. The expected number of affected
relatives adds up to 1-5 (Table II).
In order to calculate the risk to have had thrombosis
under the thrombophilia hypothesis, we first applied
Mendelian reasoning to assign a risk for carriership of the
thrombophilia trait for each relative. To this end we assume
that the index case is affected with this trait and that the trait
is inherited in an autosomal dominant fashion. Both parents
(II. l and II.4) were assigned a risk of 1/2 and the four
grandparents (1.1 to 1.4) a risk of 1/4. Subsequently,
brothers and sisters (III.l, III.2, III.3, ΙΠ.5) were assigned a
risk of 1/2, aunts and uncles (II.2, II.3, II.5, II.6) a risk of 1/4
and cousins and nieces (III.6 to III. 12) a risk of 1/8. Next, the
probability to have had thrombosis was calculated for all
family members using equation 2. Under the thrombophilia
hypothesis, the expecteed number of symptomatic relatives
adds up to 4-3.
DISCUSSION
This study demonstrates that a family history for venous
thrombosis or embolism cannot be interpreted without
considering the number of relatives and their ages. The
commonly applied criterion of a single symptomatic relative
for the family history to 'positive' (Engesser et al, 1987;
Heijboer et al, 1990) is not sufficiently strict for all but the
shortest pedigrees. When we carried out a national
thrombophilia survey in The Netherlands we found a
satisfactory explanation for thrombophilia in only one out
of three families with a positive family history (Briet et al,
1987); Heijboer et al (1990) found an even lower figure. We
explained this finding by the existence of unknown causes of
thrombophilia, which was recently shown to be true by the
finding of Dahlbäck et al (1993) and Subsequently by
ourselves (Koster et al, 1993) that many cases of idiopathic
thrombophilia are due to a resistance against activated
protein C. However, a low cut-off point for the family history
to be considered positive is bound to produce a low predictive
value for the family history.
The calculation of likelihood ratios favouring a thrombo-
philia trait äs presented here is obviously a simplification. It
is clear that some cases with thrombosis are more likely to be
associated with thrombophilia than others. A young man
with spontaneous mesenteric vein thrombosis is more likely
to suffer from antithrombin III deficiency than an 80-year-
old who has deep venous thrombosis after total hip
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replacement. The results shown in Table III do not
accornodate such Information. Similarly, we have assumed
that all inherited risk factors carry risks of the same
magnitude. For protein C and the resistance to activated
protein C this assumption is probably correct (Allaart et al,
1993; Koster et al, 1993). Whether this is also true for
antithrombin III and protein S remains to be determined, but
it is unlikely that this affects our discussion in a signiflcant
way. Furthermore, we have not taken into account the
somewhat higher thrombosis risk of women. Finally, if
objective diagnosis could be applied in all cases, the
incidence of thrombosis in the population at large äs well
äs in the protein C deficiency group would decrease.
Consequently, the overall effect on the outcome of our
calculations is probably not important. Further work is
necessary to take these considerations into account.
It will be difficult for all thrombosis centres to collect
reference data on the population at large, and even more
difficult to collect them on families with protein C deficiency
or other thrombophilias. Regional differences in the
incidence of thrombosis in either group depend more on
the ascertainment of the diagnosis than on true variations in
the thrombosis incidence. For this reason we do not think
that it is necessary to collect local data in order to apply our
approach to the family history. Another factor that is difficult
to take into account is the reliability of the family history; the
only solution for this is to persevere and to get Professional
confirmation of any information about thrombotic events.
The importance of our quantitative approach is two-fold.
First, the search for the causes of hitherto idiopathic familial
thrombophilia must be based on families with an excessive
number of patients with thrombosis, or the efforts will be
fruitless. Second, unnecessary diagnostic tests in individual
patients can be avoided if the history is used in a critical way.
Although the absolute figures in our example may be rough
approximations, we find it safe to conclude that a single
symptomatic relative is not sufficient evidence for the
presence of inherited thrombophilia in an index case with
deep vein thrombosis or pulmonary embolism.
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